Bristol Myers SquibbBMYEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
BMY Q4 2025 Key Financial Metrics
Revenue
$12.5B
Gross Profit
$8.4B
Operating Profit
N/A
Net Profit
$1.1B
Gross Margin
67.2%
Operating Margin
N/A
Net Margin
8.7%
YoY Growth
1.3%
EPS
$0.54
Financial Flow
Bristol Myers Squibb Q4 2025 Financial Summary
Bristol Myers Squibb reported revenue of $12.5B for Q4 2025, with a net profit of $1.1B (8.7% margin). Cost of goods sold was $4.1B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $12.5B |
|---|---|
| Net Profit | $1.1B |
| Gross Margin | 67.2% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Bristol Myers Squibb Annual Revenue by Year
Bristol Myers Squibb annual revenue history includes year-by-year totals (for example, 2025 revenue was $48.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $48.2B |
| 2024 | $48.3B |
| 2023 | $45.0B |
| 2022 | $46.2B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.87B | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B |
| YoY Growth | 4.7% | 8.7% | 8.4% | 7.5% | -5.6% | 0.6% | 2.8% | 1.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $99.03B | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B |
| Liabilities | $82.48B | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B |
| Equity | $16.49B | $17.02B | $17.14B | $16.34B | $17.39B | $17.43B | $18.55B | $18.47B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.83B | $2.33B | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B |
Other Health Care Companies
JNJ
Johnson & Johnson
Revenue
$24.6B
Net Profit
$5.1B
LLY
Lilly (Eli)
Revenue
$19.3B
Net Profit
$6.6B
MRK
Merck & Co.
Revenue
$17.3B
Net Profit
$5.8B
PFE
Pfizer
Revenue
$16.7B
Net Profit
$3.5B
VTRS
Viatris
Revenue
$3.7B
Net Profit
N/A
ZTS
Zoetis
Revenue
$2.4B
Net Profit
$603.0M
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M